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Objectives: Since 2008, the Caisse Nationale d’Assurance Maladie des Travailleurs 
Salariéshas set up a diabetic patient support programme in ten pilot depart-
ments in France. In addition to written advice, programme members also have 
access to telephone support from health education nurses. In 2010, the sophia 
programme was extended to another nine departments and, at the beginning of 
2013, it was generalized to all French departments. The present study evaluated 
the health economics impact of the programme after a follow-up of 3 years. This 
analysis follows a preliminary assessment that demonstrated positive results 
after 1 year. MethOds: The variation of various health care use indicators as 
well as outpatient and inpatient costs was compared between three cohorts: 
members of pilot departments, non-members, and a control group of diabetic 
patients living in departments in which sophia was not available. Results are 
adjusted for between-group differences observed at the beginning of the pro-
gramme. Results: Adjusted analysis showed that, after matching for all other 
characteristics, compliance with recommended examinations improved to a much 
greater extent among programme members than among control subjects and 
non-members. Although all health care costs continued to increase in each cohort, 
outpatient and inpatient expenditure was € 226 lower for programme members 
than for controls for the period 2009-2011: -€ 54 for outpatient care and -€ 172 
for inpatient care. Although the outpatient expenditure of programme members 
was higher (+€ 40) for outpatient visits and medical procedures, their paramedical 
expenditure was lower (-€ 89). Hospitalization rates for diabetes were significantly 
lower among members than among controls. cOnclusiOns: These results con-
firm the significant impact of the sophia programme on compliance with clinical 
practice guidelines in diabetology, hospitalization rates, and the 3-year growth of 
outpatient and inpatient costs. An assessment of the impact of the sophia pro-
gramme on clinical parameters will be conducted in the near future.
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Objectives: To evaluate the consistency of T2DM management by French GPs in 
2012 versus 2013 HAS guidelines that recommend modulating glycaemic objec-
tives depending on patient’s profile. To assess current treatment need for T2DM 
patients. MethOds: A transversal study, based on the IMS LifeLinkTM prospective 
Diabetes Cohort linked to Electronic Medical Records database (Disease Analyzer) 
was used to investigate patients’ profiles (age, disease history and complications, 
renal impairment, cardiovascular events, co-morbidities), HbA1c, hypoglycaemic 
risk, self monitoring of blood glucose (SMBG), and BMI evolution, linked to the cur-
rent treatment. Results: A total of 6680 T2DM patients (56% men) were included 
in the 2012 study cohort. The mean age was 66.6 years (25% of patients above 75 
years); 19% had moderate to severe renal impairment and 56% had cardiovascular 
history. The new HAS guidelines split patients into several categories with associ-
ated HbA1c objectives varying from 6.5% to 9% based on age, frailty, diabetes history, 
and co-morbidities. 4%, 35%, 43%, and 18% of diabetic patients were eligible for the 
6.5%, 7%, 8%, and 9% HbA1c objectives respectively. It appears that 55% of the dia-
betic population were at risk of hypoglycaemia, age and long diabetes history being 
the major risk factors. Given the modulation of glycaemic objectives more patients 
reached the new HbA1c objectives (74% of patients) vs. previous guidelines (about 
55%). In this representative cohort, SU were prescribed with no dosage adjustment 
to all patients and even more frequently to patients at risk of hypoglycaemia (60.6%) 
while DDP4i were prescribed to “healthy patients” mostly not at risk of hypoglycae-
mia (51.5%). cOnclusiOns: A minority of T2DM patients (39%) are eligible for an 
HbA1c objective of 7% or below, highlighting their frailty. This survey also shows that 
more patients are reaching their HbA1c target. However many of them are receiving 
treatments they should not due to high risk of hypoglycaemia.
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Objectives: The impact of memory problems (MPs) on patient functioning, well-
being and diabetes management is not well understood. This study examines 
these impacts in Germany and compares findings to data from US, UK, Canada 
and China. MethOds: A 5 country web-based survey was conducted. MPs were 
defined as: unintentionally forgetting to take insulin (UF), questioning if insulin 
had been taken (QT), or questioning amount of dose (QD). Results: A total of 350 
German respondents (60.0% Type 1) completed the survey, 61.1% male, mean age of 
39.5 (±13.3) and mean age of diabetes onset 30.2 (±12.6). The prevalence of MPs in the 
past month was: 74.0% UF, 82.0% QT and 68.3% QD. MPs occurred most frequently 
when waking in the morning or when relaxing. Between 27.9% (UF) – 48.3% (QD) of 
respondents skipped their insulin dose and waited for next scheduled dose when 
experiencing a MP. Patients experiencing MPs required between 2.0 (QT)–8.7 (UF) 
hours, on average, to return to normal blood glucose range, conducted between 1.2 
(QT) –4.4 (UF) extra BG monitoring tests, reported a moderate negative impact on 
their physical and emotional functioning, work absenteeism or reduced ability to 
function optimally when at work and between 3.6% (QT) and 13.8% (QD) visited/
contacted their health care provider due to MPs. Compared to the total sample 
(N= 1404), German respondents were more likely to report that their diabetes was 
very well/well controlled and that they were very/extremely confident in knowing 
what to do when they had an MP compared to respondents and were less likely 
than patients in other countries to have contact with a physician or other health 
care professional following a MP. cOnclusiOns: These findings suggest that MPs 
and 14/12% (N/D) contacted a health care professional. In the week after an event, 
respondents added an average of 2.8/3.6 (N/D) blood glucose tests to an average of 
18.8/17.4 (N/D) tests in a normal week. Nocturnal events had a high impact on sleep 
quality (46% of respondents) and social life (24%), and 84% of respondents felt tired 
and/or fatigued the next day. In the daytime survey, about 26% reported the event 
highly impacted daily activities (outside of work). Also, 40/18% (N/D) of respondents 
indicated that the event had a high impact on their fear of hypoglycaemia. The 
majority ascribed hypoglycaemia to stress (50%/58% [N/D]) or irregular/insufficient 
food intake (50%/40% [N/D]). cOnclusiOns: Both nocturnal and daytime hypogly-
caemic events had an impact on patients’ use of health care system, quality of life 
and daily productivity.
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Objectives: To investigate the clinical significance of change in QoL-AGHDA 
score after 1 year of growth hormone (GH) replacement. MethOds: Observational 
data were obtained from KIMS (Pfizer International Metabolic Database). Minimal 
important differences (MID) for the QoL-AGHDA score and its five domains (mem-
ory and concentration, tenseness, tiredness, self-confidence, and social isolation) 
were calculated using an anchor-based approach with a rating of patient-perceived 
treatment benefit and patient-reported change in need for assistance. Perception 
of treatment benefit was measured using the KIMS Patient Life Situation Form 
(PLSF), a 5-point ordinal assessment of change (much improved, a little improved, 
no change, a little worse, much worse). The effect of baseline (BL) scores on MID 
was analysed using the QoL-AGHDA thresholds included in the New Zealand (≥ 16) 
and England (≥ 11) reimbursement criteria. Results: Data from 1404 patients 
(52% female, 96% Caucasian, mean age [SD] of 45 [14] years) were included in the 
analysis. Mean GH dose [SD]was 0.20 [0.14] mg/day at BL and 0.32 [0.16] mg/day 
during Year 1. The Spearman correlation between change in QoL-AGHDA score 
and perception of treatment benefit was moderately positive (0.45; p < 0.01). The 
correlation was stronger for females and for patients with more impaired (higher) 
BL QoL-AGHDA scores. Using the anchor-based approach with patient-perceived 
treatment benefit, the MID for the QoL-AGHDA score was -4.61 at Year 1. Self-
confidence was most sensitive and tenseness least sensitive of the domains in 
predicting patient-perceived treatment benefit. Patients requiring assistance at 
BL and not at Year 1 experienced the largest mean improvement in QoL-AGHDA 
score. cOnclusiOns: Several national reimbursement authorities currently 
include the QoL-AGHDA score in eligibility criteria for access to reimbursed GH 
replacement. This is the first study to calculate the MID for the QoL-AGHDA score. 
Findings indicate that change in QoL-AGHDA score is positively correlated with 
patient-perceived treatment benefit.
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Objectives: This study examined the effects of nocturnal and daytime non-severe 
hypoglycaemic events on utilisation of health care services and patient quality of 
life in Brazil. MethOds: People with diabetes from six different countries who 
had experienced a non-severe hypoglycaemic event in the past 4 weeks were 
asked to take part in a nocturnal and/or daytime hypoglycaemia survey. In the 
Brazilian subgroup, 86 people responded (50 respondents per survey). The sur-
veys were conducted either face to face or online; hypoglycaemic events were 
self-reported. Results: In the Brazilian cohort (nocturnal [N]/daytime [D] survey, 
respectively), 80% (N)/76% (D) had type 2 diabetes, 46%/38% (N/D) were male, mean 
age was 41(N)/40(D) years and mean weight was 82.4 kg(N)/81.8 kg (D). Participants 
received treatment with insulin (53%/70% [N/D]), oral medication (61%/60% [N/D]), 
GLP-1 (0%/8% [N/D]) and/or diet and exercise (32%/45% [N/D]). Approximately a 
quarter of respondents (26%/22% [N/D]) reported that they generally experienced 
a hypoglycaemic episode at least once a week. After the non-severe nocturnal (N)/
daytime (D) hypoglycaemic event, 29% and 53% (N/D) decreased their insulin dose 
and 38% and 50%, respectively, contacted a health care professional. Participants 
used on average 13.0 or 11.5 (N/D) extra blood glucose tests the following week and 
56%/32% (N/D) of the surveyed reported a high level of fear of a hypoglycaemic event. 
Among the 44/43 (N/D) respondents who worked for pay, 48%/35% (N/D) went to 
work late or left early; 23%/9% (N/D) missed ≥ 1 full days due to the non-severe event 
and 55%/26% (N/D) said that the event highly impacted upon their productivity at 
work. cOnclusiOns: In Brazil, nocturnal and daytime non-severe hypoglycaemic 
events severely impact upon patients’ quality of life and work productivity, with half 
of patients surveyed decreasing their insulin dose and/or contacting their health 
care provider after a non-severe event.
DiaBetes/enDoCrine DisorDers – health Care use & Policy studies
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analysis of phase III registration trials (full-publication if available, and Clinical 
Trial report/study Synopsis) and EPARs of commonly used short-acting (Insulin 
Aspart and Insulin Glulisine) and pre-mix (Biphasic Insulin Aspart) insulin ana-
logues. Results: Therapy adjustments based on SMBG data were documented 
in 5/24 Insulin Aspart-, 3/18 Insulin Glulisine- and 4/15 Biphasic Insulin Aspart 
phase III registration trials. The EPARs of all three insulin analogues recommend 
the use of SMBG to adjust the insulin doses, repeatedly and throughout all sections 
in EPAR. cOnclusiOns: Overall, in 12/57 phase III registration trials the dose of 
insulin analogues was regularly adjusted based on SMBG data, and the EPARs of all 
insulin analogues explicitly recommend the use of SMBG to adjust the insulin doses. 
Therefore, the demonstrated safety and efficacy of these insulin analogues are the 
result of a complex intervention including insulin analogues, their dose adjust-
ments based on SMBG data as well as training rather than the insulin analogues 
alone. This is not consequently reflected in reimbursement schemes, in particular 
in emerging countries. Full study reports were not available for further analysis. 
These potentially would have provided deeper insights on how SMBG was used in 
the remaining 45/57 trials.
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Objectives: Little is known about routine use of basal insulins (Glargine, Detemir, 
NPH) in primary care patients with type 2 diabetes. The aim was to compare 
injection frequencies of basal insulins in type 2 diabetes (T2D) in primary care 
practices, both for basal-supported oral (BOT) and basal-bolus (ICT) treatment regi-
mens. MethOds: Primary care data from 4,503 Glargine (BOT/ICT: 2,247/1,964), 
1,373 Detemir (490/800), and 4,072 NPH-insulin (1,331/2,425) users were retrospec-
tively analysed (05/2009-04/2012). The Disease Analyzer database (IMS HEALTH) 
assembles drug prescriptions, diagnoses, basic medical and demographic data 
obtained from the practice computer system of general practitioners and special-
ists throughout Germany. The Charlson Comorbidity Index was used as generic 
marker of comorbidity. Logistic regression (> 1 daily injection) and propensitiy scores 
were used to adjust for various confounders (age, sex, type of physician, dosage, 
BMI, HbA1c). Results: Overall, more than one daily injections were observed in 
7.5% of Glargine users (BOT: 6.2%, ICT: 9.0%), which was lower than for Detemir 
(overall: 25.4%; BOT: 22.0%, ICT: 27.4%) and NPH-insulin (25.4%; BOT: 23.9%, ICT: 
27.2%) (all p< 0.001). The adjusted odds of having more than one injection was lower 
for Glargine compared to Detemir (OR; 95% CI: 0.26; 0.22-0.32) and NPH-insulin 
(0.20; 0.17-0.23). Similar results were found for BOT (Glargine vs. Detemir: 0.23; 
0.17-0.32; Glargine vs. NPH-insulin: 0.16; 0.13-0.21) and for ICT (Glargine vs. Detemir: 
0.27; 0.21-0.35; Glargine vs. NPH-insulin: 0.22; 0.18-0.27). Finally, after matching the 
groups for the propensity score, the odds for more than one daily injection was also 
significantly reduced in the Glargine group both compared to Detemir (OR; 95%CI: 
0.30; 0.24-0.37) and NPH insulin (0.25; 0.22-0.29). cOnclusiOns: Glargine is associ-
ated with significant lower injection frequencies than other basal insulins. These 
findings might impact treatment satisfaction and as a consequence quality of life, 
persistence and economic aspects of diabetes treatment.
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Objectives: To examine treatment intensification and switching patterns of 
individuals with T2DM initiating OHM. The results are compared to international 
guidelines issued in 2009. MethOds: Data were analysed using a population-based 
pharmacy claims database from January 2008 to November 2012. Incident users of 
OHM were identified for 2008-2009 as not having received OHM in the previous 12 
months. Patients dispensed insulin, > one OHM, or < 16 years were excluded from 
the study. Patients were followed until Nov-2012. Treatment intensification was 
defined as receiving an additional one, or two hypoglycaemic medicines (double or 
triple-therapy respectively). Treatment switching was defined as OHM monotherapy 
discontinuation with initiation on alternative monotherapy. Results: A total of 
24,869 patients were included in the study. Most were initiated on metformin (76.4%) 
or sulphonylureas (21.6%). Treatment intensification: 25.8% of patients initiated 
on metformin progressed to double-therapy. Sulphonylureas (61.5%), DPP-4 inhibi-
tors (23.9%) and GLP-1 agonists (6.2%) were the most frequently prescribed add-on 
treatment (median time to add-on OHM= 424days). Of those initiated on sulpho-
nylureas 32.4% progressed to double-therapy; metformin (78.4%), DPP-4 inhibitors 
(9.3%) and long-acting insulin (5%) were the most frequently prescribed (median 
time to add-on= 295days). 14.3% of patients on double-therapy progressed to triple-
therapy (median time to add-on= 434days). 26.6% of patients did not receive the 
recommended double-therapy and 64.3% received agents in their triple-therapy 
that were not recommended. Treatment Switching: Overall 7.1% switched medi-
cation. The most frequent switches were metformin to sulphonylureas (46.5%, 
median time to switch= 226days), sulphonylureas to metformin (22.5%, median 
time to switch= 330days) and metformin to DPP-4 inhibitors (6.9%, median time 
to switch= 577days). Initial OHM was significantly associated with time to switch 
(p< .0001). cOnclusiOns: Initial drug treatment followed guidelines. However, 
evidence-based practice was not closely followed for treatment intensification 
suggesting prescribers may be unaware of treatment guidelines. This data may be 
useful for assessing the potential place in therapy, and cost-effectiveness of new 
hypoglycaemic medicines.
carry financial burden, impact patients’ daily functioning and well-being and may 
be serious obstacles to optimal diabetes control. This burden may be some lower in 
Germany than other countries.
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Objectives: To examine patient characteristics, treatment patterns, and health 
care resource utilization of patients with acromegaly in the US. MethOds: Using 
a large US claims database, adult individuals with commercial insurance newly 
diagnosed with acromegaly (ICD-9-CM: 253.0) between 07/01/2007 and 12/31/2010 
were identified (the first observed diagnosis was the index date). Patients were 
required to have 6-month pre-index and 12-month post-index continuous enroll-
ment. Descriptive analysis was performed to describe demographic and clini-
cal characteristics, treatment patterns of acromegaly, and health care resource 
utilization during the post-index period. Similar analysis was conducted for 
Medicare-eligible patients with supplemental private insurance. Results: This 
study included 930 commercially-insured patients (mean age: 47.2 years; 52.0% 
female) and 104 Medicare-eligible patients (mean age: 72.8 years; 36.5% female) 
with acromegaly. For the commercial population, of the comorbidities evaluated, 
hypertension (38.2%), diabetes (25.9%), and anthropathy/arthralgia/synovitis 
(23.7%) had the highest prevalence. More than half of the patients (57.3%) received 
no treatment; 21.7% received tumor resection surgery and 21.0% received medi-
cal therapy as the first-line treatment. During the 12-month post-index period, 
one-third had inpatient hospitalization and 23.2% had emergency room visit; 
the mean physician office visit was 17.1. For the Medicare population, hyperten-
sion (67.3%), diabetes (36.5%), and anthropathy/arthralgia/synovitis (29.8%) were 
most prevalent comorbidities. About two-thirds (63.5%) received no treatment; 
8.7% received tumor resection surgery and 27.9% received medical therapy 
as the first-line treatment. More than one-third (34.6%) had inpatient hospitaliza-
tion and 26.9% had emergency room visit during the 12-month post-index period; 
the mean physician office visit was 21.1. cOnclusiOns: Our findings suggest 
high unmet needs in the population with more than half of patients with acro-
megaly being untreated. Efforts should be made to understand this untreated 
population to provide better care. Future research should investigate different 
treatment options as well as their impact on health care costs and health care 
resource utilization.
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Objectives: HbA1c concentrations predict the risk of complications in patients 
with type 2 diabetes mellitus (T2DM). This study assessed temporal trends in ele-
vated HbA1c levels in the UK primary care setting. MethOds: T2DM was identi-
fied by medical diagnosis, prescribing, elevated blood glucose and/or prescribing of 
monitoring devices. Patients had ≥ 12 months of CPRD history, with data available 
for the entire year of observation. T2DM patients prescribed insulin were excluded. 
Mean HbA1c levels and proportion of patients with elevated HbA1c were assessed 
across six years (01/04/2006–31/03/2012). Elevated HbA1c was defined according to 
the UK Quality and Outcomes Framework (QOF) threshold: > 7.5% for all years except 
2009/2010 (> 7.0%). Estimates were stratified by age-band, gender, T2DM-status and 
treatment categories. Results: Mean HbA1c levels among 176,428 patients were 
relatively stable and below threshold across the study period (2006/2007: 7.05%; 
2011/2012: 7.16%), with the exception of 2009/2010 (7.09%). Nonetheless, > 20% of 
patients had a record of elevated HbA1c in each year (36.7% in 2009/2010). Elevations 
were more common among males than females (20%-25.0% vs. 18%-20%) and among 
patients 40-59 years (27.2%-33.7 %) vs. those ≥ 60 years (15.9%-23.3%). Although 
elevations were similar among prevalent (20%-23%) and incident-T2DM (22%-23%), 
prevalent-T2DM showed an increasing trend in the proportions with an elevation 
over time, whilst incident-T2DM showed a decreasing trend. The proportion with 
elevated HbA1c varied by treatment: diet and exercise 4.8%-6.1%; monotherapy 24%; 
dual therapy 32.7%-38.0%, and; triple therapy 42%-50%. Over 80% of patients with 
elevated HbA1c were overweight or obese, > 20% had a 10-year Framingham Risk 
score > 20% (patients without existing CVD) and 17%-21% of patients had history of 
chronic renal failure. cOnclusiOns: Although mean HbA1c concentrations were 
below target (apart from 2009/2010), elevated HbA1c was present in > 20% patients 
across all years. Further efforts are needed to help patients to achieve adequate 
glycaemic control.
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Objectives: Registration trials’ purpose is to show safety and efficacy of insulin 
therapy. They are the basis of subsequent insulin reimbursement decisions. Insulin 
dosing is typically individualized: a safe and efficacious insulin therapy requires 
upfront dose finding and regular dose adjustments. These adjustments are based 
on data from Self-Monitoring of Blood Glucose (SMBG). However, some countries 
reimburse insulin analogues, but not blood glucose test strips. This analysis inves-
tigates the use of SMBG in Phase III registration trials of selected insulin analogues 
and if consequently the European Public Assessment Reports (EPARs) recommend 
the use of SMBG as part of the insulin therapy. MethOds: Systematic search and 
